Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity
Ain Shams University
40 participants
May 5, 2025
OBSERVATIONAL
Conditions
Summary
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Eligibility
Inclusion Criteria12
- Age ≥ 18 years and ≤ 65 years
- Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
- Any stage of disease (nodal or extra-nodal), with or without B symptoms
- Scheduled to receive standard systemic treatment (R-CHOP)
- ECOG performance status 0-2
- Baseline normal:
- Complete blood count (CBC)
- Hepatitis viral markers
- Liver and renal function tests
- Urine analysis
- Echocardiogram
- Additional investigations to exclude current infection if clinically indicated
Exclusion Criteria10
- History of other concurrent or previous malignancies
- Relapsed or refractory DLBCL
- Uncontrolled comorbid conditions that may interfere with study participation, including:
- Diabetes mellitus
- Autoimmune diseases
- Active infections
- Chronic inflammatory diseases
- Cardiac dysfunction
- Liver cell failure
- Pregnant females
Interventions
Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07057765